Ranbaxy: Ranbaxy Confirms 'Global' Deal Resolving Antitrust MDL

Parties in a multidistrict lawsuit against Ranbaxy Pharmaceuticals told a Boston federal judge Thursday to release their precious month of trial time after confirming it reached a $485 million global settlement to resolve claims it manipulated the U.S. Food and Drug Administration's generic drug approval process to ice out competitors.